Fraxinellone

Fraxinellone, a natural product isolated and purified from the root barks of Dictamnus dasycarpus Turcz. with neuroprotective, vasorelaxing, insecticidal, and antimicrobial activities, is a selective blocker of voltage-dependent Ca2 channel, while dictamine relaxed the rat aorta by suppressing the Ca2 influx through both voltage-dependent and receptor-operated Ca2 channels, and can dramatically induce apoptosis of activated peripheral CD4() T cells in vivo, consequently resulting in less CD4() T-cell activation and infiltration to the liver.

Product information

CAS Number: 28808-62-0

Molecular Weight: 232.28

Formula: C14H16O3

Chemical Name: 1(3H)-Isobenzofuranone, 3-(3-furanyl)-3a,4,5,6-tetrahydro-3a,7-dimethyl-, (3R-cis)- (9CI)

Smiles: CC1CCC[C@]2(C)[C@@H](OC(=O)C2=1)C1C=COC=1

InChiKey: XYYAFLHHHZVPRN-JSGCOSHPSA-N

InChi: InChI=1S/C14H16O3/c1-9-4-3-6-14(2)11(9)13(15)17-12(14)10-5-7-16-8-10/h5,7-8,12H,3-4,6H2,1-2H3/t12-,14-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (430.51 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Fraxinellone (0-100 μM；12 hours) decreases the percent of PD-L1 positive cells from 20.4% to 11.4% in A549 cells[1].

In Vivo:

Fraxinellone (oral gavage; 30 and 100 mg/kg; every three days; 30 days) significantly suppresses tumor growth, reduces HIF-1α, pTyr705 STAT3, PD-L1 and VEGF staining compared with the control group in female athymic BALB/c nude mice[1].

References:

1. Xing Y, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Pharmacol Res. 2018 Sep;135:166-180.

Products are for research use only. Not for human use.